🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Pleased to report FGFR2b expression in gastric cancer and relationship with other biomarkers ESMO Open ESMO - Eur. Oncology. The results of bemarituzumab phase 3 studies are awaited.OncoAlert OncoDaily sciencedirect.com/science/articl…

So excited to present a case of locally advanced gastroesophageal cancer for a fun discussion with Drs. David Zhen from Fred Hutch Cancer Center and Bruce Lin at Binaytara Best of ASCO, Seattle 2025. The studies we discussed include MATTERHORN, CM577, DESTINY-Gastric04, etc., all practice

Listening to our lung cancer expert Lei Deng, MD (He/Him) making a blast in his lung cancer presentation!

Phenomenal 2nd day Binaytara Best of ASCO with interactions with colleagues/friends in broader community! Stellar speakers & team based learning! Binay Shah, MD, MHA Nicole D. Fleming MD Fred Hutch Cancer Center Mazyar Shadman, MD MPH Lei Deng, MD (He/Him) Diane Tseng Hiba Khan MD MPH Lisa Tachiki, MD Easter Ho Ronan Hsieh, MD, MS Hsieh Lab

✳️I am thrilled to share I received the David Roodman Excellence in Mentoring Award this year as well. To me, there is no better award than the success and growth of my mentees, Drs Tara Magge Meghana Singh, Urvashi Joshi UPMC Heme-Onc Fellowship Program ❗️ ✳️I would like to dedicate these awards

Adding “kras is undruggable” to the Freezing Cold Takes folder (again)

Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors JAMA Oncology doi.org/10.1001/jamaon… 🔎128 studies, 343 SOTRs 👉Acute rejection: 36.2%; graft loss: 18%, lower risk w/ steroids & mTOR 👉ORR: 31% 🧐ICI my be considered in

A Real-World Experience in Pan-Tumor Testing for HER2 IHC in More Than 65 000 Solid Tumors JAMA Oncology doi.org/10.1001/jamaon… 🔎|Caris Life Sciences, Ventana anti-HER2/neu (4B5) assay 👉pan-tumor rate of HER2+:3.1% 🧐I consider Her2 testing relevant in most cancer (albeit rare in

I could not agree more! I have been really pushing neoadj consideration for all our patients with msi-h disease! We have to get surgical buy in as well in order to even be aware of these patients.

Zanidatamab plus chemotherapy as first-line treatment for HER2-positive GC/GEJ cancer The Lancet Oncology doi.org/10.1016/S1470-… 🔎single-arm, phs 2 👉ORR 76·2% 👉mPFS 12·5 mo 👉mOS 36·5 mo 🧐Looks promising, now combo w/ ICI, phs-3 awaited ESMO - Eur. Oncology

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations | Revolution Medicines #ESMOGI25 ir.revmed.com/news-releases/…

Our meta-analysis (n=12,698) shows: Omitting 5-FU bolus from GI chemo regimens → ✔️ No difference in PFS/OS 📉 Less grade 3–4 neutropenia (OR 0.46) 📉 Less thrombocytopenia (OR 0.53) YUSUF İLHAN Yakup Ergün OncoDaily OncoAlert LARVOL

NIVO + IPI vs NIVO for MSI-H/dMMR mCRC: Health-related quality of life analysis 🔎CheckMate 8HW 👉mPFS clearly improved 👉 HRQoL, less symptoms 🧐 Supports use of Nivo IPI as 1st line treatment in MSI CRC #ESMOAmbassadors #ESMOGI25 ESMO - Eur. Oncology

It's easy to recommend exercise for better overall health but I had a truly remarkable day in clinic empowering patients with colon cancer to follow an evidence-based, post-op fitness program that offers a survival benefit on par with some chemo drugs Bodies in motion, indeed!

📢 Exciting News from CAHON! We’re proud to announce that the Journal of Hematology & Oncology (JHO)—the official journal of the Chinese American Hematologist and Oncologist Network (CAHON)—has reached a new Impact Factor of 40.4, up from 29.9 in 2024. This places JHO in the top

🚨ACCORD Trial🚨 Resected Extrahepatic CCA or Gallbladder CA 🔍Randomized Adjuvant CRT + Camrelizumab vs Observation 🔥Whopping improvement in OS and RFS with CRT + ICI with persistent separate at tail of the curve!!! tinyurl.com/64yc3uum JAMA Oncology

New survival benchmark for people living with advanced #biliarytractcancer - findings in @jhepatology solidify durvalumab + GemCis as the standard first-line treatment. #cancerresearch #oncology EASLnews, via EurekAlert!! @elseviernews eurekalert.org/news-releases/…

✳️Excited to share our paper with Dr Richard Kim ❗️ In this paper, we summarized and elaborated on predictive biomarkers of immunotherapy for patients with colorectal cancer❗️ #CRCTrialsChat COLONTOWN PALTOWN Foundation Fight Colorectal Cancer Few take-home messages 👇 shorturl.at/YWI76

It’s my great honor to write the editorial for the pivotal MATTERHORN study NEJM Yelena Y. Janjigian MD ASCO More global collaboration is needed to further improve outcomes for our patients with gastric/GEJ cancer.OncoAlert OncoDaily nejm.org/doi/full/10.10…

Dr Amol Akhade Also, 2 practical clinical pearls. 🧬MET is not uncommon in patients with Cancer of Unknown Primary (CUP) that end up being #cholangiocarcinoma. 💊Crizotinib while approved for ALK and ROS1 fusions, it’s actually a good MET⛔️too. Cholangiocarcinoma Foundation OncoAlert 🔗link.springer.com/article/10.100…